RxDoctor Payments Data

Jillian Volnek, PA

Physician Assistant · Lincoln, NENPI 1083924617

Payments from drug & device makers

$3,655in general payments, 2019–2025

Across 102 payments — averaging $35.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$1K
  • Aimmune Therapeutics, Inc.$791
  • Novo Nordisk$409
  • Gilead$216
  • Corcept Therapeutics$209
  • Lilly USA, LLC$133
  • plus $811 from 21 others

What the payments were for

  • Travel & lodging$87824%
  • Food & beverage$2,76676%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,655 in reported general payments places this provider in the 90th percentile of 1,127 physician assistant providers in Nebraska.

See all physician assistant providers in Nebraska

Medicare billing

Part B allowed, 2024
$29,548
Medicare patients
81
Services billed
667

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide129$139,983
Humalog Kwikpen U-200Insulin Lispro63$139,535
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/762$122,949
TrulicityDulaglutide99$112,779
Tresiba Flextouch U-200Insulin Degludec78$100,822
MounjaroTirzepatide41$43,403
Humulin R U-500Insulin Regular, Human24$41,993
JardianceEmpagliflozin40$41,736
Soliqua 100-33Insulin Glargine/Lixisenatide30$35,825
FarxigaDapagliflozin Propanediol28$18,760
Tresiba Flextouch U-100Insulin Degludec37$15,640
Novolog FlexpenInsulin Aspart50$14,713
Trijardy XrEmpaglifloz/Linaglip/Metformin14$13,554
Lantus SolostarInsulin Glargine,hum.Rec.Anlog99$11,468
Humalog Kwikpen U-100Insulin Lispro30$11,443

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro, Humalog, Insulin Lispro$133$170,487191 claims
Novo NordiskOzempic$409$139,983129 claims
Boehringer IngelheimJardiance, Trijardy Xr$54$55,29054 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$30$35,82530 claims
MerckJanuvia$14$6,34311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,127 physician assistant providers in Nebraska.

Other physician assistant in Lincoln

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →